SBP Group (Sino Biopharmaceutical Limited) confirmed that 15.35 million ordinary shares repurchased in March 2026 were cancelled on 16 April 2026.
The cancellation reduced the company’s issued share capital from 18.76 billion to 18.75 billion shares, representing a 0.08% contraction in the share base.
The shares were bought back at a volume-weighted average price of HKD 5.8542, implying a total cash outlay of approximately HKD 89.86 million.
Following the cancellation, the company reported no remaining treasury shares.
Company secretary Lai Kuen filed the disclosure under Hong Kong Listing Rule 13.25A.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments